Fresh or Cryopreserved Leukopaks? Assessing the Impact of Different Storage Conditions on Leukopak Stability

Join Dr. Wassim Basheer from Charles River Laboratories as he shares impactful data looking at stability of fresh and cryopreserved leukopaks.

Immune cell viability is crucial for ensuring the success of basic research, cell-based assays, or for the development of effective cell therapies. Thus, there has been great interest in identifying ideal storage parameters for protecting leukopak cellular integrity from collection to transit and processing. Even though it can be challenging to determine which leukopak storage temperature is most suitable for your specific needs, emphasis should be placed on preserving consistency, flexibility, global accessibility, and simplified cold chain logistics.

Join us for a webinar with Dr. Wassim Basheer as he shares valuable findings from Charles River highlighting the effects of different leukopak storage temperatures on immune cell viability over time, so you can make an informed choice on which leukopak storage parameters best suit your project requirements.

Key Topics Include:

Standardized leukopak collection parameters to maintain consistency
Advantages and challenges when using fresh or cryopreserved leukopaks
Effect of different storage temperatures on stability of immune cells in leukopaks

Presenters

Wassim Basheer, PhD

Senior Product Manager
Cell Solutions
Charles River Laboratories

Dr. Wassim Basheer is a senior product manager at Charles River-Cell Solutions, focusing on developing and optimizing the portfolio of human-derived biomaterials which are critical for accelerating advancements in cell therapy and drug development.

Watch Webinar

Production Partner

Charles River Cell Solutions

Charles River Cell Solutions, (formerly HemaCare & Cellero) is a global leader in the supply and customization of research (RUO) and GMP grade human-derived immune cells and stem cells. With 45+ years of experience, we provide controlled, consistent, high quality, and purified human biological products and unprocessed cellular material.

VIEW PROFILE

Additional Content From Scientist.com

How to Avoid Expensive Redesign Cycles in Antibody Discovery

Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.

Beyond Exposure: Integrating PK/PD for Translational Predictive Power

Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.

Related Content

Engineering Neuromodulation for Cardiovascular Instability

Dr. Aaron Phillips traces the translational journey of a discovery that began in a foundational laboratory and is now advancing through pivotal clinical trials aimed at stabilizing cardiovascular function.

From Clinical Data to Actionable Assets for Pharmaceutical R&D

In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.

Translational Success in Inflammasome Drug Discovery: How Advanced Models and Integrated Assays Can Reduce Attrition

Join Professor Luke O’Neill (Trinity College Dublin) and Dr Elise Malavasi ( Associate Director of Neurosciences Concept Life Sciences) for this webinar that explores recent advances in inflammasome science, and highlights how selecting appropriate in vitro models and meaningful readouts is essential for accurately assessing therapeutic potential.